Rachael Jacoby, MD
Ophthalmology · Salt Lake City, UTNPI 1265659213
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 32.7% of the total. 2025 is the largest year on record at $454, 2.5 times the $181 reported in 2019. That places this record below the midpoint for ophthalmology clinicians in UT, where the typical reported total is $987.
Across 29 payments — averaging $36.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$345
- Astellas Pharma US Inc$284
- Carl Zeiss Meditec, Inc.$173
- Genentech USA, Inc.$94
- AbbVie$68
- Apellis Pharmaceuticals, Inc.$30
- plus $60 from 3 others
Across 28 payments — averaging $4334.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$112K
- Regeneron$10K
What the payments were for
- Food & beverage$1,03498%
- Gifts$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 9 | $345 |
| Astellas Pharma US Inc | 8 | $284 |
| Carl Zeiss Meditec, Inc. | 2 | $173 |
| Genentech USA, Inc. | 4 | $94 |
| AbbVie(2 entities) | 2 | $68 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Eyepoint US, Inc. | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Alcon | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$132
- EYLEA$111
- CIRRUS HD-OCT$103
How this compares
$1,054 in reported general payments places this provider in the 50th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 78 | $2,994 |
| MoxifloxacinMoxifloxacin Hcl | 38 | $1,045 |
| Ketorolac Tromethamine | 17 | $552 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $296 |
| Timolol Maleate | 18 | $228 |
| Brimonidine Tartrate | 14 | $209 |
| Latanoprost | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.